Related Experiment Video
Updated: May 11, 2026

Swimming Exercise Protocol and Care Methods for Pregnant Rats
Published on: April 5, 2024
Repeat antenatal steroid exposure and later blood pressure, arterial stiffness, and metabolic profile
Hanna Norberg1, Johanna Stålnacke, Anna Nordenström
1Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Objective:
To determine the relationship between repeat courses of antenatal corticosteroids (ACS) and risk factors for cardiovascular disease in adolescents and young adults.
Study Design:
We assessed body mass index, blood pressure, arterial stiffness, blood lipids, and insulin resistance (IR) in a Swedish population-based cohort (n = 100) at a median age of 18 (range 14-26) years. Fifty-eight subjects (36 males) had been exposed to 2-9 weekly courses of antenatal betamethasone and 42 (23 males) were unexposed subjects matched for age, sex, and gestational age (GA).
Results:
There were no significant differences between the groups regarding body mass index, systolic or diastolic blood pressures, arterial stiffness measured by augmentation index, blood lipids, IR, or morning cortisol levels either in simple regression or in multivariable models. However, more subjects with elevated augmentation index had been exposed to repeat courses of ACS (n = 7) compared with unexposed subjects (n =1, P = .06), and glucose, insulin, and IR correlated inversely to GA at start of ACS (P < .01).
Conclusions:
Repeat courses of ACS did not correlate to adverse cardiovascular risk profile in adolescence and young adulthood, but long-standing effects on the arterial tree and glucose metabolism, the latter dependent on GA at ACS exposure, cannot be excluded. These observations have clinical implications for the ongoing discussion on short-term benefits and long-term safety of repeat ACS treatment.
Related Concept Videos
Hormonal Regulation
Teratogenicity
Hypertension II: Pathophysiology
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Angiotensin II Receptor Blockers
